Skip to main content

Advertisement

Table 3 In-hospital management of ACS patients with diabetes/possible diabetes

From: Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project

  STEMI NSTE-ACS
Diabetes/possible diabetes (N = 14,650) No diabetes (N = 25,143) p value Diabetes/possible diabetes (N = 9230) No diabetes (N = 14,427) p value
DAPT, % (n/N) 95.4 (13,911/14,577) 95.5 (23,915/25,037) 0.686 89.4 (8130/9098) 90.0 (12,827/14,250) 0.108
 Aspirin, % (n/N) 96.3 (14,032/14,579) 96.5 (24,163/25,038) 0.184 93.1 (8469/9100) 93.6 (13,343/14,253) 0.099
 P2Y12 inhibitors, % (n/N) 96.9 (14,194/14,643) 96.7 (24,295/25,135) 0.134 92.7 (8534/9211) 92.9 (13,394/14,411) 0.395
GPIIb/IIIa, % (n/N) 39.8 (5816/14,625) 38.4 (9651/25,112) 0.008 17.5 (1612/9196) 17.3 (2494/14,406) 0.668
Anticoagulant, % (n/N) 79.4 (11,632/14,643) 79.2 (19,912/25,135) 0.606 68.1 (6273/9211) 67.1 (9668/14,411) 0.104
 UFH 5.3 (768/14,623) 4.5 (1121/25,097) < 0.001 2.0 (185/9171) 1.9 (271/14,379) 0.472
 LMWH 73.0 (10,676/14,623) 73.7 (18,490/25,097) 0.147 62.8 (5760/9171) 62.4 (8969/14,379) 0.505
 Fondaparinux sodium 1.3 (186/14,623) 1.0 (262/25,097) 0.038 2.2 (201/9171) 1.6 (232/14,379) 0.001
 Other anticoagulants 1.9 (280/14,623) 2.0 (512/25,097) 0.389 2.0 (185/9171) 2.0 (280/14,379) 0.707
Statins, % (n/N) 94.1(37,382/39,735) 94.0 (13,748/14,628) 0.544 92.9 (8562/9212) 93.4 (13,459/14,408) 0.161
Beta-blockers, % (n/N) 64.3 (2917/4536) 62.5 (4998/7997) 0.044 67.6 (2046/3028) 66.4 (3431/5164) 0.295
ACEI/ARB, % (n/N) 49.8 (6687/13,427) 48.4 (11,151/23,030) 0.011 54.0 (4643/8606) 48.8 (6535/13,396) < 0.001
PCI, % (n/N) 77.1 (11,289/14,650) 77.5 (19,484/25,143) < 0.001 58.2 (5367/9230) 61.1 (8810/14,427) 0.006
 Time of PCIa, % (n/N) (h)    < 0.001    0.006
  < 2 55.2 (8574/15,526) 57.4 (5220/9100)   10.0 (734/7341) 8.9 (388/4383)  
  2–11.9 10.2 (1577/15,526) 11.5 (1046/9100)   10.0 (731/7341) 10.8 (474/4383)  
  12–23.9 3.2 (493/15,526) 3.4 (313/9100)   7.8 (572/7341) 7.2 (314/4383)  
  24–71.9 9.8 (1524/15,526) 8.9 (809/9100)   31.2 (2293/7341) 29.5 (1294/4383)  
  ≥ 72 21.6 (3358/15,526) 18.8 (1712/9100)   41.0 (3011/7341) 43.7 (1913/4383)  
 Type of stentsb, % (n/N)    0.010    0.088
  Drug eluting stent 98.1 (9827/10,017) 98.1 (16,825/17,145)   96.9 (4317/4456) 96.7 (6997/7235)  
  Bare metal stent 1.0 (101/10,017) 1.2 (213/17,145)   1.8 (82/4456) 1.6 (113/7235)  
  Other 0.9 (89/10,017) 0.6 (107/17,145)   1.3 (57/4456) 1.7 (125/7235)  
CABG, % (n/N) 0.5 (46/10,121) 0.5 (94/17,328) 0.324 0.7 (33/4670) 0.7 (51/7583) 0.824
Length of stay, median (IQR), day 10.0 (7.0–13.0) 10.0 (7.0–13.0) < 0.001 10.0 (7.0–13.0) 9.0 (7.0–12.0) < 0.001
  1. STEMI ST-segment elevation myocardial infarction, NSTE-ACS non-ST-segment elevation acute coronary syndrome, DAPT dual antiplatelet therapy, UFH unfractionated heparin, LMWH low molecular weight heparin, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting
  2. The usage rate of drugs was calculated in patients without drug contraindications
  3. a Time of PCI, time from admission to PCI, and detailed data of time of PCI were not available for 8600 patients with PCI
  4. b Type of stents and type of PCI were not available for 849 patients with stent implantation